A Randomized, Double-Blind, Placebo-Controlled Multicenter Study to Evaluate the Efficacy and Safety of CAL02 Administered Intravenously in Addition to Standard of Care in Subjects with Severe Community-Acquired Bacterial Pneumonia (SCABP)

Project: Research project

Project Details

StatusActive
Effective start/end date3/8/243/7/28

Funding

  • Eagle Pharmaceuticals Inc: $12,788.46